CTOs on the Move

Southwestern Health

www.southwesternhealth.org

 
Southwestern Health Resources, which blends the strengths of University of Texas Southwestern Medical Center and Texas Health Resources, includes a network of 29 hospital locations and more than 5,000 physicians, committed to being the national leader in population health. With more than 500 points of access to care, this provides for higher value and allows patients to access services across a full continuum of medical needs. The network serves people across 17 counties in North Texas. In total, Southwestern Health coordinates care for more than 650,000 patients, aligned with commercial health care plans and Medicare programs. SWHR operates the nation`s ...
  • Number of Employees: 250-1000
  • Annual Revenue: $100-250 Million

Executives

Name Title Contact Details
Shashi Vangala
 Chief Data Analytics and Value Creation Officer Profile
Thomas Marlow
 Chief Information Officer Profile

Similar Companies

Hospice of Central Michigan

Hospice of Central Michigan, Inc. is a Mount Pleasant, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Capital District Physicians` Health Plan

Founded in 1984 as a physician-founded and guided health plan, CDPHP and its affiliates currently serve members in 24 counties throughout New York with a full family of products.

Nevada Health Centers

Nevada Health Centers, Inc. is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Nevada Health Centers, Inc. is based in Carson City, NV. You can find more information on Nevada Health Centers, Inc. at www.nvrhc.org

ETEK Services

ETEK Services is a Fort Lauderdale, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ovid Therapeutics

Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovid`s drug candidate, OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid has initiated the Phase 2 STARS trial of OV101 in adults with Angelman syndrome and a Phase 1 trial in adolescents with Angelman and Fragile X syndrome to identify doses suitable for younger patients.